<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01112449</url>
  </required_header>
  <id_info>
    <org_study_id>PSHCI 08-012</org_study_id>
    <nct_id>NCT01112449</nct_id>
  </id_info>
  <brief_title>Influence of Selenium on Prostate Cancer Related Biomarkers</brief_title>
  <official_title>Influence of Selenium on Prostate Cancer Related Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Penn State Milton S. Hershey Medical Center researchers are trying to compare the effects of
      two different forms of selenium (selenium yeast and selenomethionine) on blood selenium
      levels and biomarkers of oxidative stress as primary endpoints. One in six men are at risk of
      getting prostate cancer in their lifetime. Participants will be asked to take
      over-the-counter selenium yeast supplements and selenomethionine or a placebo for nine out of
      twelve months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will conduct a double-blind, randomized, placebo-controlled clinical study of selenium
      supplementation in the form of L-selenomethionine (SM)(200 µg/day) and selenium-enriched
      yeast (SY) (200 µg/day and 285 µg/day) for 9 months; the 285 µg/day SY is selected to deliver
      an equivalent selenium as in 200 µg/day SM to healthy men. The variability of SM in SY that
      will be used here is less than 3% and it accounts for 70.5% of the SM content in SY. As
      primary endpoints, we will determine the effects of these two forms of selenium on plasma
      levels of selenium and its metabolites as well as biomarkers of oxidative stress at several
      time points. As a secondary endpoint, the effect of these two forms of selenium on plasma PSA
      levels will be examined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers of oxidative stress</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of selenium and selenium metabolites</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Effect of Selenium on Oxidative Stress in Healthy Men</condition>
  <arm_group>
    <arm_group_label>Low dose selenized-yeast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 µg/day of selenized-yeast (SY)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>selenomethionine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The second group will receive 200 µg/day of selenomethionine (SM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>no active medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose selenized-yeast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The fourth group will receive 285 µg/day of selenized-yeast (SY).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>no active medication</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>selenomethionine</intervention_name>
    <description>200 µg/day of selenomethionine (SM)</description>
    <arm_group_label>selenomethionine</arm_group_label>
    <other_name>SM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>low dose selenized-yeast</intervention_name>
    <description>200 µg/day of SY</description>
    <arm_group_label>Low dose selenized-yeast</arm_group_label>
    <other_name>low dose selenium-enriched yeast</other_name>
    <other_name>SY</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>high dose selenized-yeast</intervention_name>
    <description>285 µg/day of SY</description>
    <arm_group_label>High dose selenized-yeast</arm_group_label>
    <other_name>high dose selenium-enriched yeast</other_name>
    <other_name>SY</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No history or evidence of diabetes

          -  Male between the ages of 20-79

          -  PSA levels ≤ 4.0 ng/mL

          -  Not taking &gt;50 µg/day selenium as a dietary supplement including multi- vitamins

          -  Non-smoker

          -  No concurrently participating or have participated in any other clinical trial within
             at least 30 days of registration

          -  Health male

        Exclusion Criteria:

          -  Evidence of prostate cancer

          -  Evidence of liver or kidney disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karam El-Bayoumy, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State Milton Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2010</study_first_posted>
  <last_update_submitted>July 8, 2015</last_update_submitted>
  <last_update_submitted_qc>July 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Karam El-Bayoumy</investigator_full_name>
    <investigator_title>Professor of Biochemical and Molecular Biology</investigator_title>
  </responsible_party>
  <keyword>selenium</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>PSA</keyword>
  <keyword>glucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

